多奈哌齐-话题@MedSci - 梅斯（MedSci）

#多奈哌齐#

11篇内容 | 1240人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1754500, encodeId=48e71e54500b9, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症, objectType=article, longId=301200, objectId=5b2c3012001e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b2c3012001e, replyNumber=0, likeNumber=96, createdTime=2022-12-24, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b2c3012001e, moduleTitle=FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5b2c3012001e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754499, encodeId=67e01e54499c7, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准, objectType=article, longId=220576, objectId=c4e22205e609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e22205e609, replyNumber=0, likeNumber=92, createdTime=2022-01-13, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e22205e609, moduleTitle=ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4e22205e609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展, objectType=article, longId=186520, objectId=88ea186520c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ea186520c4, replyNumber=0, likeNumber=76, createdTime=2020-07-16, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ea186520c4, moduleTitle=Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=88ea186520c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754498, encodeId=48a11e5449841, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=FDA已接受ADLARITY（多奈哌齐透皮系统）的NDA以治疗阿尔茨海默病, objectType=article, longId=186923, objectId=4f8d18692353, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8d18692353, replyNumber=0, likeNumber=83, createdTime=2020-06-01, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8d18692353, moduleTitle=FDA已接受ADLARITY（多奈哌齐透皮系统）的NDA以治疗阿尔茨海默病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4f8d18692353)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754496, encodeId=475f1e544963a, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=2016 亚太地区应用多奈哌齐23mg治疗中至重度阿尔兹海默病的临床建议, objectType=article, longId=82990, objectId=1688829907e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1688829907e, replyNumber=0, likeNumber=64, createdTime=2017-07-31, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1688829907e, moduleTitle=2016 亚太地区应用多奈哌齐23mg治疗中至重度阿尔兹海默病的临床建议, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1688829907e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754495, encodeId=3a2e1e54495ac, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=FDA批准美金刚胺/多奈哌齐(Namzaric)组合药剂用于治疗阿尔茨海默氏症, objectType=article, longId=44982, objectId=a2c14498213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c14498213, replyNumber=0, likeNumber=81, createdTime=2015-12-19, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c14498213, moduleTitle=FDA批准美金刚胺/多奈哌齐(Namzaric)组合药剂用于治疗阿尔茨海默氏症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a2c14498213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754494, encodeId=f6371e54494b1, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请, objectType=article, longId=31581, objectId=e44e31581e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44e31581e0, replyNumber=0, likeNumber=79, createdTime=2014-11-03, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44e31581e0, moduleTitle=Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e44e31581e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754493, encodeId=e3b21e54493ad, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=ASCO 2013：脑放疗后用多奈哌齐不改善认知功能, objectType=article, longId=19979, objectId=e601199e9f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e601199e9f6, replyNumber=0, likeNumber=79, createdTime=2014-04-21, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e601199e9f6, moduleTitle=ASCO 2013：脑放疗后用多奈哌齐不改善认知功能, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e601199e9f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754492, encodeId=07ab1e54492b4, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=欧盟评估多奈哌齐的神经阻滞剂恶性综合征风险, objectType=article, longId=11936, objectId=597e119361b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597e119361b, replyNumber=0, likeNumber=88, createdTime=2013-09-14, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597e119361b, moduleTitle=欧盟评估多奈哌齐的神经阻滞剂恶性综合征风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=597e119361b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754490, encodeId=8d301e54490e5, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=NEJM：中重度阿尔茨海默病患者宜继续服用多奈哌齐, objectType=article, longId=4617, objectId=497a461e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=497a461e1c, replyNumber=0, likeNumber=83, createdTime=2012-08-14, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=497a461e1c, moduleTitle=NEJM：中重度阿尔茨海默病患者宜继续服用多奈哌齐, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=497a461e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754491, encodeId=73851e5449116, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, objectTitle=NEJM研究启示：治疗中重度AD，多奈哌齐是理想选择, objectType=article, longId=4676, objectId=779c46e619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779c46e619, replyNumber=0, likeNumber=91, createdTime=2012-09-06, rootId=0, userName=shanyongle, userId=c5fb36698279, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779c46e619, moduleTitle=NEJM研究启示：治疗中重度AD，多奈哌齐是理想选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=779c46e619)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多奈哌齐

2020-05-29

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症

2022-12-24

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

ICURE用于治疗阿尔茨海默氏症痴呆的多奈哌齐贴剂全球首次获得品种许可批准

2022-01-13

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展

2020-07-16

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

FDA已接受ADLARITY（多奈哌齐透皮系统）的NDA以治疗阿尔茨海默病

2020-06-01

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

2016 亚太地区应用多奈哌齐23mg治疗中至重度阿尔兹海默病的临床建议

2017-07-31

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

FDA批准美金刚胺/多奈哌齐(Namzaric)组合药剂用于治疗阿尔茨海默氏症

2015-12-19

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请

2014-11-03

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

ASCO 2013：脑放疗后用多奈哌齐不改善认知功能

2014-04-21

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

欧盟评估多奈哌齐的神经阻滞剂恶性综合征风险

2013-09-14

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

NEJM：中重度阿尔茨海默病患者宜继续服用多奈哌齐

2012-08-14

shanyongle (审核中...)

前往app查看评论内容

#多奈哌齐#

NEJM研究启示：治疗中重度AD，多奈哌齐是理想选择

2012-09-06

科室
- - 订阅+
  - 更多科室
工具
服务